FGFR2 and non-small cell lung carcinoma: Approximately 20% of squamous cell carcinomas and 3–5% of adenocarcinomas have FGFR1 amplification, while about 1–3% of NSCLC cases have FGFR2 and FGFR3 fusions [80].